ERBB2 and breast cancer: In the subset analysis also based on breast cancer subtypes, Black patients with refractory and sensitive disease had a higher mortality risk compared with White patients in the corresponding disease groups (refractory: HR+ subtype, HR, 1.51; 95% CI, 1.41-1.62; P < .001; ERBB2+, HR, 1.51; 95% CI, 1.35-1.70; P < .001; TNBC, HR, 1.19; 95% CI, 1.11-1.27; P < .001; sensitive: HR+ subtype, 1.17; 95% CI, 1.04-1.30; P < .001; ERBB2+, HR, 1.31; 95% CI, 1.14-1.52; P < .001; TNBC, HR, 1.13; 95% CI, 1.03-1.24; P < .001).